Possible gatifloxacin-induced hypoglycemia

OBJECTIVE: To report a case of hypoglycemia in a patient receiving gatifloxacin for presumed exacerbation of chronic obstructive pulmonary disease (COPD). CASE SUMMARY: A 73-year-old white man with an extensive past medical history significant for type 2 diabetes mellitus and COPD was prescribed gatifloxacin 400 mg/d for a COPD exacerbation. After 2 days of therapy, the patient presented to the emergency department (ED) reporting worsening symptoms; he had a blood glucose concentration of 22 mg/dL. Because he had not eaten well for several days, the patient discontinued his oral antidiabetic medications prior to presenting to the ED, but continued to take gatifloxacin. The patient had never before experienced a symptomatic hypoglycemic episode during the years of taking his antidiabetic medications. In the ED, he received 1 last dose of gatifloxacin and was treated aggressively with intravenous dextrose. By the end of his hospitalization, antidiabetic medication was restarted to control hyperglycemia. DISCUSSION: Although gatifloxacin has been shown to alter glucose homeostasis, the mechanism of action has not been elucidated. Other recognized risk factors that contribute to the development of hypoglycemia are discussed. Our patient experienced hypoglycemia after receiving gatifloxacin and recovered 24 hours after discontinuation. The Naranjo probability scale suggests a possible drug-related event. CONCLUSIONS: The temporal relationship of gatifloxacin administration and the hypoglycemic episode suggests that gatifloxacin likely precipitated the event. Clinicians should be aware of this adverse effect in patients taking gatifloxacin presenting with hypoglycemia.

This article has been cited by other articles:

				A. J Mehlhorn and D. A Brown Safety Concerns with Fluoroquinolones Ann. Pharmacother., November 1, 2007; 41(11): 1859 - 1866. [Abstract] [Full Text] [PDF]

				K. L. Edwards, R. G. Hall, and M. E. Ceja Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature Journal of Pharmacy Practice, February 1, 2007; 20(1): 93 - 102. [Abstract] [PDF]

				R. Zvonar Gatifloxacin-induced dysglycemia. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2087 - 2092. [Abstract] [Full Text] [PDF]

				L. Y. Park-Wyllie, D. N. Juurlink, A. Kopp, B. R. Shah, T. A. Stukel, C. Stumpo, L. Dresser, D. E. Low, and M. M. Mamdani Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults N. Engl. J. Med., March 30, 2006; 354(13): 1352 - 1361. [Abstract] [Full Text] [PDF]

				S. E. Brogan and M. K. Cahalan Gatifloxacin as a Possible Cause of Serious Postoperative Hypoglycemia Anesth. Analg., September 1, 2005; 101(3): 635 - 636. [Abstract] [Full Text] [PDF]

				A. R Donaldson, J. R Vandiver, and C. K Finch Possible Gatifloxacin-Induced Hyperglycemia Ann. Pharmacother., April 1, 2004; 38(4): 602 - 605. [Abstract] [Full Text] [PDF]

				R. G. Cregin Current Management Issues Associated with Community-Acquired Pneumonia Journal of Pharmacy Practice, October 1, 2003; 16(5): 324 - 334. [Abstract] [PDF]

				K. M. Smith and B. M. Lomaestro What Role do Fluoroquinolone Antimicrobial Agents Play in Cardiac Dysfunction and Altered Glycemic Control? Journal of Pharmacy Practice, October 1, 2003; 16(5): 349 - 360. [Abstract] [PDF]